sorafenib has been researched along with Central Nervous System Neoplasm in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Dai, M; Fan, Z; Huang, F; Huang, J; Liang, X; Liu, H; Liu, Q; Nie, D; Shi, P; Sun, J; Sun, Q; Wang, Z; Xu, J; Xu, N; Xuan, L; Yu, G; Zhang, X; Zhang, Y | 1 |
| Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Tang, Y; Tye, G; Yacoub, A | 1 |
1 trial(s) available for sorafenib and Central Nervous System Neoplasm
| Article | Year |
|---|---|
A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia.
Topics: Central Nervous System; Central Nervous System Neoplasms; Graft vs Host Disease; Humans; Leukemia; Recurrence; Retrospective Studies; Sorafenib | 2022 |
1 other study(ies) available for sorafenib and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Survival; Central Nervous System Neoplasms; Drug Synergism; fas Receptor; Histone Deacetylase Inhibitors; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |